CVS HEALTH CORP. REGISTERED SHARES DL-,01
Technische Signale
| Signale Details | |
|---|---|
| WKN / ISIN | - / US1266501006 |
| Börse | Düsseldorf |
| Schluss | 55,09 |
| Konservatives Signal |  23.09.24 |
| MACD | 03.09.24 |
| Momentum |  19.07.24 |
| Bollinger Bands | 15.04.24 |
| TBI | 26.09.24 |
| Schnitt GD 90 | - |
Analystenbewertung
| Bewertungstrend | aktuell | Vorwoche | Vormonat |
|---|---|---|---|
| Bewertung | 2,18 | 2,25 | 2,25 |
| Anzahl der Analysten | 28 | 28 | 28 |
| Kaufen | 9 | 8 | 8 |
| Übergewichten | 5 | 5 | 5 |
| Halten | 14 | 15 | 15 |
| Untergewichten | 0 | 0 | 0 |
| Verkaufen | 0 | 0 | 0 |
| Aktueller Durchschnitt von insgesamt 28 Analysten: 2,18 | |||
| Planzahlen (in EUR) | 2023 | 2024(e) | 2025(e) |
|---|---|---|---|
| Umsatz | 357,78 Mrd. | 369,29 Mrd. | 387,19 Mrd. |
| EBIT | 12,40 Mio. | 14,70 Mrd. | 16,02 Mrd. |
| EBITDA | 16,31 Mio. | 17,38 Mrd. | 19,13 Mrd. |
| Nettoverschuldung** | 51,80 Mrd. | 50,99 Mrd. | 47,76 Mrd. |
Umsatz |
EBIT |
EBITDA |
Nettoverschuldung** |
| Dividende | 2023 | 2024(e) | 2025(e) |
|---|---|---|---|
| Dividende / Aktie | 2,17 EUR | 2,66 USD | 2,76 USD |
| Dividendenrendite | 4,08% | 4,51% | 4,67% |
Dividende / Aktie (in USD) |
Dividendenrendite (in %) |
||
| Analystenhäuser |
|---|
| Accountability Research Corporation,Argus Research Company,Atlantic Equities LLP,Avondale Partners,Baird,Baptista Research,Barclays,BMO Capital Markets Equity Research,BMO Capital Markets U.S. (Historical),BofA Global Research,Cantor Fitzgerald & Co.,Caris & Company,CFRA Equity Research,Citadel Securities, LLC,Citigroup Inc,Cleveland Research Company,Collins Stewart LLC,Cowen Securities LLC,Credit Suisse,Crisp Idea,Deutsche Bank,Equisights,Evercore ISI,FBR Capital Markets & Co.,G. Research, LLC,Goldman Sachs,Guggenheim Securities, LLC,Hanwha Investment & Securities Co., Ltd.,HSBC,Inside Research S.A.,ISI Group Inc.,J.P. Morgan,Jefferies LLC,JMP Securities,Lazard Capital Markets,Leerink Partners LLC,Loop Capital Markets,Macquarie Research,Mizuho Securities USA LLC,Morgan Stanley,Morningstar Inc.,Needham & Company,NH Investment & Securities Co., Ltd.,Oppenheimer & Co. Inc.,Piper Sandler Companies,Raymond James & Associates,RBC Capital Markets,Sanford C. Bernstein & Co., LLC,Seaport Research Partners,Stephens, Inc.,Stifel, Equities Research,Susquehanna Financial Group, LLLP,TD Cowen,Thomas Weisel Equity Research,Tigress Financial Partners LLC,Truist Securities,UBS Investment Bank,Wells Fargo Securities, LLC,William Blair & Company L.L.C.,Wolfe Research, LLC.,Zephirin Group, Inc. |
| Hinweis |
|---|
|
Selected Data supplied by Standard & Poors
* Unabhängige Schätzung (Gewinnwachstum (in %)) ** Nettobargeldbestand bei negativen Schätzungen |